Clinical trials
Thrombotic Thrombocytopenic Purpura (TTP) clinical trials
Below are recruiting thrombotic thrombocytopenic purpura (ttp) clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06928233Recruiting
TNF gene study in immune TTP patients
This study looks at a specific gene (TNFAIP3) in people who have had immune-mediated thrombotic thrombocytopenic purpura (iTTP). It aims to understand how this gene might be linked to the condition. Participants will provide a blood or DNA sample for genetic testing.
MilanAges 12 years+ - NCT05571774Recruiting
Building a database for severe ADAMTS13 deficiency
This trial is creating a research database for people with severe ADAMTS13 deficiency, a condition where the body has very low activity of a key blood-protein. It may help researchers better understand the condition by collecting and organizing patient information.
Suzhou, JiangsuAges Any age - NCT05914441Recruiting
TTP registry for patients in Spain and Portugal
This is a real-world registry that collects information about people diagnosed with thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal. It helps researchers understand TTP patterns and outcomes, and participation is voluntary.
Seville, AndalusiaAges Up to 99 years - NCT05950750Recruiting
Living with aTTP? Join a national patient registry study
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
AnkaraAges 18 years+ - NCT06291025Recruiting
Testing a simpler treatment for immune-mediated TTP
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
AmiensAges 18 years+ - NCT06376786Recruiting
Italian iTTP Registry for acute episodes
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
Milan, MIAges 12–99 - NCT06441578Recruiting
Study of a treatment for congenital TTP
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
TokyoAges Any age - NCT06945861Recruiting
Immune aspects of TTP study
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
RouenAges 18 years+ - NCT07205861Recruiting
Study of patients with immune TTP in France
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
ParisAges Any age - NCT07353099Recruiting
Study of Adzynma in cTTP patients
This study observes children and adults with cTTP who have already used Adzynma. It aims to gather more information about the treatment's real-world effects.
ViennaAges Any age - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65
Hear when a new Thrombotic Thrombocytopenic Purpura (TTP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thrombotic thrombocytopenic purpura (ttp)?
- Yes. Clin2 currently lists 11 recruiting thrombotic thrombocytopenic purpura (ttp) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thrombotic thrombocytopenic purpura (ttp) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thrombotic thrombocytopenic purpura (ttp) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.